An elevated tumor mutational burden (TMB) in the blood has now demonstrated its potential as a reliable clinical biomarker for predicting the clinical efficacy of the checkpoint inhibitor Tecentriq (atezolizumab, Roche Holding AG) in treating patients with advanced non-small-cell lung cancer (NSCLC), a Sino-U.S. study has shown.

A collaborative study by Harvard University and Chinese researchers has identified a previously unrecognized and clinically prevalent class of Mycobacterium tuberculosis variants that alter propionate metabolism and mediate multidrug tolerance, thereby driving drug resistance.

A collaborative study by Harvard University and Chinese researchers has identified a previously unrecognized and clinically prevalent class of Mycobacterium tuberculosis variants that alter propionate metabolism and mediate multidrug tolerance, thereby driving drug resistance.

The finding that subcellular inhibitors of heat shock protein 70 (Hsp70) promote cancer cell death via different mechanisms may lead to novel cancer chemotherapies, by showing the importance of studies of small-molecule subcellular locations and functions in elucidating their detailed mechanisms of action.

HONG KONG – A University of Hong Kong (HKU) study has shown that a new small-molecule non-antibiotic compound has potent efficacy against methicillin-resistant Staphylococcus aureus (MRSA), making it a promising lead compound for developing anti-virulence drugs against S. aureus.

Japanese scientists at the Center for induced Pluripotent Stem (iPS) Research and Application (CiRA) at Kyoto University have shown for the first time that small levels of turbulence in blood promote the generation of platelets.

Japanese scientists at the Center for induced Pluripotent Stem (iPS) Research and Application (CiRA) at Kyoto University have shown for the first time that small levels of turbulence in blood promote the generation of platelets.